S
Tariq Arshad
Senior manager, WW commercial development, Pfizer
ROLE MODEL: Fred Hassan
HAS: "Infectious enthusiasm for my work"
Tariq Arshad has seen pharma's resource-strapped, generic-bedeviled future—and he's here to say that it can be handled. The experience came in his native Pakistan about 10 years ago. Arshad, after burning out as a pediatric oncologist, was working for Pharmacia & Upjohn. His challenge: maintain sales of the anxiety drug Xanax, even with hundreds of generic competitors.
Tariq Arshad
He arrived in New York a month after 9/11, survived the Pfizer–Pharmacia merger, and soon found himself working on doomed Exubera. Today, he handles both marketing and early commercial for Pfizer's Alzheimer's portfolio. "Anybody who aspires to a marketing leadership role has to spend time in the trenches, so to speak, working with R&D to optimize the commercial value of their assets," says Arshad. "Without doing that really, we won't be effective marketers once the product reaches launch stage."
These days, Arshad sees tactics at Pfizer he hasn't seen since Pakistan—a flattening structure, fewer marketing resources, and a willingness to learn how to compete with generics. It's an environment where he's already proved that he can thrive.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.